5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Product Type (Diagnostic Tests, Reproductive & Genetic Products, Vaccines and Drugs), Application and Geography
Fastest Growing Market:
A significant rise in focus toward cloning and transgenic animals is expected to propel the market growth. The Annual Statistics of Scientific Procedures on Living Animals Great Britain 2017, published by the UK Government, states that in 2017, 3.79 million procedures were carried out in the United Kingdom involving living animals, out of which, 1.89 million were carried out for experimental purposes, and 1.90 million were counted under the breeding of genetically altered animals. As per the report published by the US Food and Drug Administration (FDA), in 2017, scientists have successfully cloned many livestock species, such as cattle, swine, sheep, and goats. Globally, animal cloning has gained popularity and acceptance, as a method to produce genetically identical animals, which is expected to fuel the market growth.
In addition to the aforementioned factor, increasing R&D activities by major market players, and the rising regulatory approvals are expected to propel the market growth over the forecast period.
As per the scope of the report, Animal biotechnology refers to the branch of biotechnology, which deals with the molecular biology techniques for producing genetically engineered animals (whose genome are modified), in order to make them suitable for pharmaceutical, industrial or agricultural applications.
|By Product Type|
|Reproductive & Genetic Products|
|Development of Animal Pharmaceuticals|
|Food Safety and Drug Development|
Report scope can be customized per your requirements. Click here.
Based on Product Type, it is segmented into Diagnostic Tests, Reproductive & Genetic Products, Vaccines, and Drugs. The growth of the vaccine segment is mainly attributed to the rising burden of animal diseases. These diseases are naturally transmitted from animals to humans, due to the consumption of contaminated food and water or by direct contact with infected animals or humans. Vaccination is an effective way to reduce disease burden in animals and plays an important role in preventive health and disease control. According to Veterinary Cancer Society estimates, every year more than 6 million cats and dogs are diagnosed with cancer in the United States. Moreover, the increasing demand for meat and animal-based products, rising pet adoption and increasing awareness regarding animal health are expected to fuel the growth of the vaccine segment over the forecast period.
To understand key trends, Download Sample Report
North America is expected to dominate the animal biotechnology market over the forecast period, owing to the factors, such as the increasing animal meat consumption, growing prevalence of various animal diseases, and the rising animal healthcare expenditure. The data published by the American Pet Products Association, in 2018, states that the total pet healthcare expenditure has been estimated to be USD 72.13 billion, while that in 2017 was found to be USD 69.51 billion. In addition, the growing awareness about animal health among the pet owners, rising government initiatives, and rise in product innovation (such as new vaccine launches) are some other factors propelling the growth of the animal biotechnology market in North America.
To understand geography trends, Download Sample Report.
The global players into the animal biotechnology market are Bayer AG, Biogenesis Bago, Boehringer Ingelheim GmbH, Ivaoes, LLC, Merck & Co.,Inc., Pfizer Inc., Santa Cruz Biotechnology, Inc., Virbac and Zoetis Inc.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Activities by Major Market Players
4.2.2 Growing Focus Towards Cloning & Transgenic Animals
4.3 Market Restraints
4.3.1 Ethical Issues Associated with Animal Biotechnology Products
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Diagnostic Tests
5.1.2 Reproductive & Genetic Products
5.2 By Application
5.2.1 Development of Animal Pharmaceuticals
5.2.2 Food Safety and Drug Development
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Biogenesis Bago
6.1.3 Boehringer Ingelheim GmbH
6.1.4 Ivaoes, LLC
6.1.5 Merck & Co.,Inc.
6.1.6 Pfizer Inc.
6.1.7 Santa Cruz Biotechnology, Inc.
6.1.9 Zoetis Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments